Канада - англійська - Health Canada

bristol labs division of bristol-myers squibb - bleomycin sulfate - powder for solution - 15unit - bleomycin sulfate 15unit - antineoplastic agents

Канада - англійська - Health Canada

fresenius kabi canada ltd - bleomycin (bleomycin sulfate) - powder for solution - 15unit - bleomycin (bleomycin sulfate) 15unit - antineoplastic agents

Канада - англійська - Health Canada

sandoz canada incorporated - bleomycin (bleomycin sulfate) - powder for solution - 15unit - bleomycin (bleomycin sulfate) 15unit - antineoplastic agents

Мальта - англійська - Medicines Authority

synthon hispania, s.l. calle castello 1, 08830 sant boi de llobregat, barcelona, spain - deferasirox - film-coated tablet - deferasirox 90 mg - all other therapeutic products

Мальта - англійська - Medicines Authority

synthon hispania, s.l. calle castello 1, 08830 sant boi de llobregat, barcelona, spain - deferasirox - film-coated tablet - deferasirox 360 mg - all other therapeutic products

Мальта - англійська - Medicines Authority

synthon hispania, s.l. calle castello 1, 08830 sant boi de llobregat, barcelona, spain - deferasirox - film-coated tablet - deferasirox 180 mg - all other therapeutic products

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

vihsdia enterprise - champeneia griffithiana radix; castanopsis radix; bamingtonia racemosa radix -

Ізраїль - англійська - Ministry of Health

taro international ltd, israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 100 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib taro is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib taro is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib taro is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib taro is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.